organization · Reporting owner
Presidio Management Group X LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date March 16, 2021 · Filed March 18, 2021
Jointly reported with US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, Tansey Casey M
Section 16 reporting ended · disclosed 2021-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 2,619,872 |
Reported balance
After 2021-03-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-16 · Other · Disposed 2,619,872 · Balance 2,619,872 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 83,813 |
Reported balance
After 2021-03-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-03-16 · Other · Disposed 83,814 · Balance 83,813 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 685,827 |
Reported balance
After 2021-03-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-03-16 · Other · Acquired 685,827 · Balance 685,827 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by PMG X. | 0 |
Reported balance
After 2021-03-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-03-16 · Other · Disposed 685,827 · Balance 0 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Tansey | 242,988 |
Reported balance
After 2021-03-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-03-16 · Other · Acquired 77,296 · Balance 242,988 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.
F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.
eFFECTOR Therapeutics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
Jointly reported with US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, Tansey Casey M, ROOT JONATHAN D
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 3,981,940 |
Last balance in matching sequence
After 2022-08-03 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 127,569 |
Last balance in matching sequence
After 2022-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2021 Filed Dec 1, 2021 23:31 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 799 | $6.70 | $5,349.31 |
DisclosureSEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 141,960 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 23:31 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 24,965 | $6.70 | $167,140.68 |
DisclosureSEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,437,369 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 26, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 156 | $7.01 | $1,093.25 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 142,759 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 26, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 4,870 | $7.01 | $34,148.44 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,462,334 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 1,132 | $7.36 | $8,325.86 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 142,915 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 35,388 | $7.36 | $260,278.74 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,467,204 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 461 | $7.40 | $3,413.24 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 144,047 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 21:43 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 14,418 | $7.40 | $106,736.45 |
DisclosureSEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,502,592 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 812 | $7.86 | $6,382.32 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 144,508 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 25,371 | $7.86 | $199,416.06 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,517,010 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 224 | $8.12 | $1,818.88 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 145,320 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 7,017 | $8.12 | $56,985.06 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,542,381 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 519 | $8.53 | $4,426.03 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 145,544 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:12 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 16,226 | $8.53 | $138,375.33 |
DisclosureSEC source: 0001062993-21-011394 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,549,398 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $9.12, inclusive for sales on 11/18/21; prices ranging from $8.04 to $8.24, inclusive for sales on 11/19/21; prices ranging from $7.75 to $8.06, inclusive for sales on 11/22/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 317 | $9.13 | $2,893.58 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 146,063 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 9,918 | $9.13 | $90,521.59 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,565,624 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 257 | $9.42 | $2,420.94 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 146,380 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 8,062 | $9.42 | $75,935.98 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,575,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 157 | $9.81 | $1,540.01 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 146,637 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 00:55 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 4,914 | $9.81 | $48,211.25 |
DisclosureSEC source: 0001062993-21-011097 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,583,604 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.16, inclusive for sales on 11/15/21; prices ranging from $9.25 to $9.58, inclusive for sales on 11/16/21; prices ranging from $8.90 to $9.35, inclusive for sales on 11/17/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 372 | $10.07 | $3,746.04 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 8 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 146,794 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 11,628 | $10.07 | $117,093.96 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 7 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,588,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 373 | $10.37 | $3,867.26 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 147,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 11,644 | $10.37 | $120,724.99 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,600,146 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 1,054 | $10.44 | $10,999.54 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 147,539 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 32,946 | $10.44 | $343,824.46 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,611,790 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 893 | $11.00 | $9,826.57 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 148,593 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 22:52 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | SaleCommon Stock | 27,892 | $11.00 | $306,923.57 |
DisclosureSEC source: 0001062993-21-010758 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,644,736 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.57 to $11.82, inclusive for sales on 11/9/21; prices ranging from $10.22 to $10.72, inclusive for sales on 11/10/21; prices ranging from $10.16 to $10.56, inclusive for sales on 11/11/21; and prices ranging from $10.00 to $10.22, inclusive for sales on 11/12/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4 F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 77,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000016 · edgar.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Tansey Disclosed balance after: 242,988 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000016 · edgar.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X. Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000016 · edgar.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X. Disclosed balance after: 685,827 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 83,814 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000016 · edgar.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 83,813 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:37 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 2,619,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000016 · edgar.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 2,619,872 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | SaleCommon Stock | 20,000 | $66.38 | $1,327,600.00 |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 7 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Lewis Disclosed balance after: 40,883 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.52 to $67.32, inclusive for sales on 11/18/2020. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 34,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 12 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly held by Krausz childrens trusts Disclosed balance after: 34,576 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. F7 · ownership.nature: Held by affiliated trusts for the benefit of Krausz children. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 34,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 11 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly held by Krausz childrens trusts Disclosed balance after: 34,576 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. F7 · ownership.nature: Held by affiliated trusts for the benefit of Krausz children. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 11,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 10 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly held by family trust controlled by Krausz Disclosed balance after: 11,794 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 67,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 9 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Tansey Disclosed balance after: 67,730 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 56,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 8 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly held by family trust controlled by Matteucci Disclosed balance after: 56,173 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 60,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Lewis Disclosed balance after: 60,883 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 37,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Federman Disclosed balance after: 37,268 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 587,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 587,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 587,851 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 71,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 167,627 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:12 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 2,245,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000024 · edgar.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 5,239,744 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP") and USVP X Affiliates Fund , L.P. ("AFF X" and, together with USVP X, the "USVP Funds", and may be deemed to have sole voting and dispositive power over the securities held by the USVP Funds. Jonathan Root, a director of the Issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci, and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Jan 21, 2021 22:59 UTC Amendment | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 67,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000006 · edgar.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly held by Casey M.Tansey. Disclosed balance after: 165,692 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · balance_after: The original Form 4 filed on November 19, 2020, is being amended by this Form 4 amendment solely to correct an adminstrative error, which incorrectly underreported the amount of shares indirectly owned by the Reporting Person listed in column 5 as 67,730 shares instead of 165,692.shares. F3 · ownership.nature: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMGX Distribution. Shares are held directly by the Reporting Person. Read SEC document |
| May 27, 2020 Filed May 28, 2020 00:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries C Preferred Stock · Derivative | 72,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 13 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 0 Underlying: Common Stock · 72,887 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein Read SEC document |
| May 27, 2020 Filed May 28, 2020 00:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries C Preferred Stock · Derivative | 2,278,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 12 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 0 Underlying: Common Stock · 2,278,331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein Read SEC document |
| May 27, 2020 Filed May 28, 2020 00:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries B Preferred Stock · Derivative | 92,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 11 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 0 Underlying: Common Stock · 92,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein Read SEC document |
| May 27, 2020 Filed May 28, 2020 00:56 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries B Preferred Stock · Derivative | 2,899,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001548538-20-000010 · edgar.xml · derivative · entry 10 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner Lewis Richard W. · CIK 0001534399 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 0 Underlying: Common Stock · 2,899,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible on a one-to-one basis into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.